PPD Inc. is taking a stake in privately held Syrrx Inc. as part of a drug development deal. The companies agreed to partner their resources in further developing Syrrx-designed human dipeptidyl peptidase-IV (DP4) inhibitors for Type II diabetes and other diseases. (BioWorld Today) Read More
